AMax101

Alexander Maxwell

AMax101’s Activity

Thu Jul 24

CAPS Underperform Pitch

AMax101 wrote about MannKind Corp (MNKD) . 11:33 AM

MNKD Underperform

Afrezza sales will be a disappointment. Labeling issues will restrict doctors from actually prescribing the drug. Predicting another Exubera bust.

Caps Pick

AMax101 made a pick in CAPS. 11:33 AM

MannKind Corp (MNKD) will Underperform the S&P 500
NL

Article

AMax101 published an article 8:09 AM

Will FDA Labelling Be MannKind's Downfall?

While FDA approval may have come wrapped in a pretty box for shareholders, what is inside the box in terms of FDA warnings could be a huge problem for MannKind and Afrezza.

Wed Jul 2

NL

Article

AMax101 published an article 5:01 PM

Is There Any Hope for Dendreon?

With large debt and a history of net losses, is it too little too late to turn around Dendreon?

Fri Jun 27

NL

Article

AMax101 published an article 5:00 PM

3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir

For companies involved in the development of drugs, a PDUFA decision will meaningfully impact their stocks. With this in mind, there are several PDUFA decisions in upcoming months to watch for.

Wed Jun 18

NL

Article

AMax101 published an article 10:15 AM

The Race To The Market: Anacor and Valeant

Anacor and Valeant are both developing new drugs for Onychomycosis. Can the both succeed in this niche market?

Mon Jun 16

NL

Article

AMax101 published an article 4:31 PM

3 Stocks with FDA Catalysts Incoming

For many companies, FDA decisions represent the hallmark of years of investment. Due to the amount of time and money that was spent developing these drugs, they can also represent significant catalysts for investors.

Sun Jun 8

NL

Article

AMax101 published an article 3:30 PM

3 Biotech Stocks with Oncoming Catalysts

For these three companies, trial results will make a big difference.

Wed May 28

NL

Article

AMax101 published an article 5:43 PM

As Orexigen Faces FDA Will Weight Loss Landscape Change?

As Orexigen once again faces FDA approval, it appears as though the landscape for weight loss drugs may once again change.

Tue Aug 27

NL

Article

AMax101 published an article 2:38 PM

The Changing Landscape in Chronic Diabetic Foot Ulcers

After the release of phase 3 data, Osiris Pharmaceuticals has just changed the dynamics of the chronic diabetic foot ulcer market. Other companies will, of course, be affected by Osiris' clinical data.

CAPS Stats & Trivia

CAPS Player Rating 42.04
Player Rank 43495 out of 75039
Score -179.51
Score Change Today +1.35
Accuracy 52.00%
Active Picks 13
Total Picks 26
Best Pick ATSX (+136.53)
Worst Pick KOG (-157.39)
Average Score per Pick -6.90
Charms Earned 2
Highest Rated Favorite No Favorites Selected
Go to AMax101’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show AMax101’s 10 Latest Posts